David Herrmann — ASN Events
  1. Schedule
  2. David Herrmann

David Herrmann

Garvan Institute / Kinghorn Cancer Centre, NSW, Australia

  • This delegate is presenting an abstract at this event.
Dr David Herrmann is a Group Leader at the Garvan Institute of Medical Research (Sydney, Australia) with major focus on improving our understanding of pancreatic cancer progression, metastasis and treatment resistance. Using genetically-engineered mice and 3D cell culture models combined with live imaging technologies, he assesses new anti-cancer treatments and treatment combinations in pancreatic cancer with the aim to improve outcomes in this deadly disease.
Presentations this author is a contributor to:

Co-targeting thrombospondin-1 (THBS-1) to improve KRAS inhibitor and chemotherapeutic efficacy in pancreatic cancer (#268)

5:35 PM
Victoria M Tyma
Poster Session 2

Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq (#266)

5:35 PM
Michael Trpceski
Poster Session 2

Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer (#153)

5:40 PM
Katie Gordon
Welcome Reception & Poster Session 1

Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response (#235)

5:35 PM
Brooke Pereira
Poster Session 2

Pancreatic cancer secretome reveals PCSK9 as a co-target to sensitise tumours to chemotherapy and reduce metastasis (#244)

5:35 PM
Shona Ritchie
Poster Session 2

Targeting the NPY/NPY1R signaling axis impairs metastasis and tissue wasting in pancreatic cancer (#159)

5:40 PM
David Herrmann
Welcome Reception & Poster Session 1

Identifying and targeting treatment response mechanisms to improve Gemcitabine/Abraxane performance in Patient-Derived Models of Pancreatic Cancer (#263)

5:35 PM
Alice Tran
Poster Session 2